mission

Glioblastoma (GBM) remains one of the most aggressive and lethal cancers, with a median survival of only 15 months and no therapeutic progress in over two decades.

The challenge lies in its immunosuppressive tumor microenvironment, dominated by myeloid cells that exhaust T-cell function and promote tumor growth.

Technology

While CAR-T therapies have shown remarkable success in blood cancers, their efficacy in solid tumors remains limited due to key challenges such as an immunosuppressive tumor microenvironment and antigen escape.

Market Opportunities

Next-generation CAR-T approaches that overcome these barriers represent a major therapeutic and commercial opportunity.

  • High unmet need in glioblastoma
  • Conventional CAR-T is limited
  • Opportunity for dual-action CAR-T
  • Strong growth in next-gen immunotherapy

Global IP protection strategy:

– Exclusive worldwide rights to the license (University of Basel)
– PCT national phase entered in major jurisdictions

Global Glioblastoma Market Size

The global glioblastoma market is expected to double over the next decade, driven by a significant unmet medical need.

GlioCART’s DUAL-ACTION CAR-T THERAPY

GlioCART’s dual-action CAR-T therapy combines direct tumor killing with reprogramming tumor-associated macrophages into tumor-killing cells, with the potential to enable durable responses to redefine outcomes for patients with glioblastoma